Boston Scientific Says It Will Miss 2026 Sales and Profit Targets After Cyberattack

Boston Scientific announced that it now appears unlikely to meet its 2026 sales and profit targets following a cyberattack. The company stated that the attack has negatively impacted its operations and supply chain, which will be reflected in its financial performance. In the statement, it was noted that mitigating the effects of the attack and restoring systems to normal will take time. The cyberattack has caused disruptions in the company's manufacturing and distribution processes, and as a result, sales may fall below expected levels in the short term. Despite this adverse development, Boston Scientific acknowledged that it will not compromise its long-term growth strategy, but its 2026 targets need to be revised. Company officials said they will make additional investments to strengthen cybersecurity measures and have launched a comprehensive review to prevent such incidents from recurring. They also noted that the current financial position is strong and that they have the flexibility to overcome such external shocks. Analysts believe this development could put pressure on Boston Scientific's stock performance, but the strength of the company's core operations may sustain investor confidence in the long run. The financial guidance the company updates in the coming period will shape the market's new expectations. This is not investment advice.